Nyxoah SA Ordinary Shares - NYXH STOCK NEWS

Nyxoah, a medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York. CEO Olivier Taelman will present on June 5 at 7:30 am ET. The presentation will be webcast and available on Nyxoah's Investor Relations website. The company will also hold 1-on-1 meetings with institutional investors. Lyxoah’s Investor Presentation is available in the Shareholder Information section of its Investor Relations page.

Nyxoah SA, listed on Euronext Brussels and Nasdaq under the symbol NYXH, disclosed updated information on its share capital and voting rights as of June 3, 2024. The company reported a share capital of EUR 5,902,793.43, with a total of 34,360,390 ordinary shares, each carrying one voting right.

Additionally, there are warrants issued under various ESOP programs from 2018 to 2022, potentially adding 2,221,000 ordinary shares to the total number of voting rights. This information complies with Article 15 of the Law of 2 May 2007, regarding the disclosure of large shareholdings.

On June 3, 2024, Nyxoah announced the receipt of four transparency notifications in compliance with Belgian law. This follows significant changes in shareholding.

FMR acquired 4.99% of voting rights, crossing the 3% threshold. BlackRock Inc. also crossed the 3% threshold and now holds 3.28% of voting rights.

Together Partnership and Gilde Healthcare passively decreased their holdings below the 10% threshold to 8.63% and 8.62%, respectively.

These notifications reflect notable shifts in Nyxoah's shareholder base.

On May 31, 2024, Nyxoah, a medical technology company focused on treating Obstructive Sleep Apnea (OSA), announced the closing of an underwritten public offering in the United States. The offering included both public and private shares, raising $50 million (EUR 45.9 million) from 5,374,755 shares at $9.25 (EUR 8.54) per share. Furthermore, underwriters exercised their option to purchase an additional 300,000 shares, bringing total gross proceeds to $52.5 million (EUR 48.5 million). The proceeds will be used for commercialization in the U.S., clinical research, R&D for the Genio system, and general corporate purposes. The closing for the additional shares is expected on June 3, 2024, subject to customary closing conditions. Cantor Fitzgerald & Co. acted as the sole book-running manager, and Degroof Petercam was the co-manager.

On May 28, 2024, Nyxoah announced updates regarding its share capital and voting rights, following the issuance of new shares. As per Belgian law, the total share capital now stands at EUR 5,851,253.43.

The company has 34,060,390 ordinary shares, each carrying a voting right. Additionally, there are rights to subscribe to unissued securities under various Employee Stock Option Plans (ESOPs), which could potentially add 2,222,500 voting securities if fully exercised.

This disclosure aligns with regulatory requirements to keep shareholders informed about changes in capital structure.

Nyxoah, a medical technology company focusing on obstructive sleep apnea (OSA) treatments, announced the pricing of its underwritten public offering. The offering includes 5,374,755 ordinary shares at $9.25 per share, potentially raising approximately $50 million. Additionally, underwriters have a 30-day option to purchase up to 806,213 more shares. The offering aims to fund U.S. pre-commercialization activities, clinical data gathering, research, and general corporate purposes. The closing is expected on May 28, 2024, contingent upon customary conditions. Cantor Fitzgerald & Co. is the sole book-running manager, with Degroof Petercam as co-manager.

Nyxoah, a medical technology company specializing in Obstructive Sleep Apnea (OSA) solutions, announced a reduction in the maximum shares available under its at-the-market equity offering program. The original cap of 6,000,000 ordinary shares has been decreased by 1,569,139 shares, bringing the new total to 4,430,861 shares. Consequently, 3,662,699 shares remain available for issuance. This adjustment increases the authorized capital by EUR 269,579. The announcement does not constitute a sale offer or solicitation. For more details, refer to section 1.5.2 of the May 22, 2024 board report on Nyxoah's investor page.

Nyxoah, a medical technology company specializing in treatments for Obstructive Sleep Apnea (OSA), announced a proposed public offering of ordinary shares in the U.S. on May 22, 2024. This offering may also include private sales to institutional investors outside the U.S. All shares are offered by Nyxoah, with no selling stockholders involved. The underwriters may purchase up to an additional 15% of shares. Proceeds will support U.S. commercialization, clinical data collection, R&D for the Genio system, and general corporate purposes. The offering is subject to market conditions and may not be guaranteed. Cantor Fitzgerald & Co. and Degroof Petercam are managing the offering.

Nyxoah reported financial and operating results for Q1 2024 on May 14, 2024. Key highlights include the DREAM U.S. pivotal study achieving co-primary endpoints, with a median AHI reduction of 70.8% and a 12-month AHI responder rate of 63.5%. The company recorded €1.2 million in sales, a 170% increase from Q1 2023. However, the operating loss increased to €12.2 million from €11.4 million last year mainly due to higher R&D expenses. The cash position was €44.3 million, down from €57.7 million at the end of 2023. CEO Olivier Taelman emphasized the positive study results and the company's readiness for a U.S. launch by the end of 2024.